Lithium

Lithium

SCHEMBL7174887

CCCCOc1ccc(PC(=O)c2c(OC)cccc2OC)c(OCCCC)c1.[Li]

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
THRB P10828 2/20 0.42
THRA P10827 1/20 0.42
PPARA Q07869 2/20 0.41
PPARG P37231 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MEN1 O00255 1/20 0.40
GAA P10253 1/20 0.40
KMT2A Q03164 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
FAAH O00519 1/20 0.39
MAPT P10636 3/20 0.39
LMNA P02545 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7174883 0.98 THRB (0.42) THRBTHRAPPARAPPARGSMN1; SMN2
SCHEMBL7175103 0.95 THRB (0.46) THRBTHRAPPARAMAPTLMNA
Lithium SCHEMBL7180963 0.95 KMT2A (0.42) THRBTHRASMN1; SMN2KMT2ACA12
SCHEMBL7181178 0.94 THRA (0.47) THRBTHRAPPARA
Lithium SCHEMBL7181773 0.93 MEN1 (0.42) THRBTHRAPPARAPPARGSMN1; SMN2
SCHEMBL7180946 0.93 KMT2A (0.42) THRBTHRASMN1; SMN2KMT2ACA12
Lithium SCHEMBL7187103 0.92 THRA (0.43) THRBTHRASMN1; SMN2MEN1GAA
Lithium SCHEMBL7180985 0.91 THRA (0.43) THRBTHRAPPARAMEN1GAA
SCHEMBL7181770 0.91 MEN1 (0.42) THRBTHRAPPARAPPARGSMN1; SMN2
Lithium SCHEMBL7179783 0.89 THRA (0.47) THRBTHRAMEN1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 THRB 2119/4885THRA 1901/4885PPARA 3039/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 THRB 2521/4885THRA 2159/4885PPARA 2624/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.